In my book any talk of an R/S is a moot point. If the forthcoming combo results are as we suspect coupled with what I believe will be amazing news regarding the first ten patients in the GVHD study - it's pretty much game over by end of first quarter.
When I listen to the excitement in Dr. Burger's voice when he speaks of the "stunning" results in the animal models and how PRO-140 COMPLETELY prevented any signs of GVHD in the mice when given a lethal dose of humanized bone marrow stem cells, how these animals were all healthy months later AND had developed new human immune systems - well that's just astonishing stuff.
And shareholders aren't the only parties taking notice. He further states during the Q & A portion of the conference that they're 'already in discussions with SEVERAL potential partners and submitted to them data from animal models - and that data has been perceived very well"-
If results break our way, probably bought by end of March--
News 
Market Data 
Discover 
